{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:42:19Z","timestamp":1773416539907,"version":"3.50.1"},"reference-count":48,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec id=\"st1\">\n<jats:title\/>\n<jats:p>Psoriatic arthritis (PsA), a systemic disease, has multi-domain musculoskeletal pathologies along with dermatological manifestations. The current recommendations and the standard of care for the treatment of PsA is to address the domain-based pathologies and the disease severity of the six clinical domains unique to PsA, namely, arthritis of the large and small joints, skin involvement, nail involvement enthesitis, dactylitis and axial disease. With currently available therapies, there are good numbers of primary\/secondary non-responders and there are added concerns because of intolerance and adverse effects. In that respect, JAK\/STAT inhibitors bring new options for many such patients with psoriasis and PsA. Here, we will discuss currently approved JAK inhibitors for PsA and the others which are in different phases of development, including the TYK2 inhibitors.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_29_2023","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T10:13:51Z","timestamp":1689243231000},"page":"186-191","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Janus kinase inhibitors for the treatment of psoriatic arthritis"],"prefix":"10.25259","volume":"90","author":[{"given":"Sanchita","family":"Raychaudhuri","sequence":"first","affiliation":[{"name":"Department of Dermatology, School of Medicine, University of California, Davis, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchi","family":"Jayeshbhai Shah","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs, VA Sacramento Medical Center, Northern California Health Care System, Mather, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smriti K.","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, School of Medicine, University of California, Davis, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siba P.","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs, VA Sacramento Medical Center, Northern California Health Care System, Mather, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"10.25259\/IJDVL_29_2023\/ref-1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"key":"10.25259\/IJDVL_29_2023\/ref-2","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-3","doi-asserted-by":"publisher","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","article-title":"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis","volume":"34","author":"Chandran","year":"2010","journal-title":"J Autoimmun"},{"key":"10.25259\/IJDVL_29_2023\/ref-4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1046\/j.1525-1470.2000.01746.x","article-title":"A comparative study of pediatric onset psoriasis with adult onset psoriasis","volume":"17","author":"Raychaudhuri","year":"2000","journal-title":"Pediatr Dermatol"},{"key":"10.25259\/IJDVL_29_2023\/ref-5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.25259\/IJDVL_29_2023\/ref-6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/0378-6323.125472","article-title":"Prevalence and clinical patterns of psoriatic arthritis in Indian patients with psoriasis","volume":"80","author":"Kumar","year":"2014","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_29_2023\/ref-7","first-page":"73","article-title":"Total-body 18F-FDG PET\/CT imaging: A tool for diagnosis and quantifying inflammatory burden of psoriatic arthritis","volume":"Suppl 9","author":"Raychaudhuri","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_29_2023\/ref-8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_29_2023\/ref-9","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1016\/0005-2760(75)90154-x","article-title":"Psoriatic arthritis: Epidemiology, clinical features, course, and outcome","volume":"64 64;Suppl 2","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/09546630600823369","article-title":"Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists\u2019 offices","volume":"17","author":"Gottlieb","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_29_2023\/ref-11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American college of rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_29_2023\/ref-12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.25259\/IJDVL_29_2023\/ref-13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-14","doi-asserted-by":"crossref","first-page":"108536","DOI":"10.1016\/j.clim.2020.108536","article-title":"Updated therapies for the management of psoriatic arthritis","volume":"220","author":"Toussi","year":"2020","journal-title":"Clin Immunol. Clin Immunol"},{"key":"10.25259\/IJDVL_29_2023\/ref-15","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_29_2023\/ref-16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate methotrexate as monotherapy monotherapy or in combination for psoriatic arthritis: Primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_29_2023\/ref-17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3899\/jrheum.190677","article-title":"Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: Systematic review with meta-analysis","volume":"47","author":"Zardin-Moraes","year":"2020","journal-title":"J Rheumatol"},{"key":"10.25259\/IJDVL_29_2023\/ref-18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/BOR.0000000000000810","article-title":"Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: Rationale and evidence for JAK inhibition","volume":"33","author":"Raychaudhuri","year":"2021","journal-title":"Curr Opin Rheumato"},{"key":"10.25259\/IJDVL_29_2023\/ref-20","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.25259\/IJDVL_29_2023\/ref-21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"10.25259\/IJDVL_29_2023\/ref-22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.0105-2896.2005.00220.x","article-title":"JAK3, severe combined immunodeficiency, and a new class of immunosuppressive drugs","volume":"203","author":"Pesu","year":"2005","journal-title":"Immunol Rev"},{"key":"10.25259\/IJDVL_29_2023\/ref-23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm"},{"key":"10.25259\/IJDVL_29_2023\/ref-24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4103\/0019-5154.62752","article-title":"SCID mouse model of psoriasis: A unique tool for drug development of autoreactive T-cell and Th-17 cell-mediated autoimmune diseases","volume":"55","author":"Raychaudhuri","year":"2010","journal-title":"Indian J Dermatol"},{"key":"10.25259\/IJDVL_29_2023\/ref-25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"10.25259\/IJDVL_29_2023\/ref-26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13075-017-1249-5","article-title":"Mechanistic rationales for targeting interleukin-17A in spondyloarthritis","volume":"19","author":"Raychaudhuri","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.25259\/IJDVL_29_2023\/ref-27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2016-211046","article-title":"Regulatory role of the JAK STAT kinase signaling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.clim.2010.05.003","article-title":"Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population","volume":"136","author":"Chen","year":"2010","journal-title":"Clin Immunol"},{"key":"10.25259\/IJDVL_29_2023\/ref-29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.mrfmmm.2010.01.017","article-title":"Genetic factors in chronic inflammation: Single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn\u2019s disease in a New Zealand population","volume":"690","author":"Ferguson","year":"2010","journal-title":"Mutat Res"},{"key":"10.25259\/IJDVL_29_2023\/ref-30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jdermsci.2011.11.011","article-title":"Podoplanin expression in wound and hyperproliferative psoriatic epidermis: Regulation by TGF\u03b2 and STAT3 activating cytokines, IFN\u03b3, IL6, and IL22","volume":"65","author":"Honma","year":"2012","journal-title":"J Dermatol Sci"},{"key":"10.25259\/IJDVL_29_2023\/ref-31","first-page":"440","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1STAT signalling in rheumatoid arthritis","volume":"71","author":"Boyle","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-33","doi-asserted-by":"publisher","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS One"},{"key":"10.25259\/IJDVL_29_2023\/ref-34","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1111\/1756-185X.13732","article-title":"Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET","volume":"22","author":"Raychaudhuri","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-35","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.25259\/IJDVL_29_2023\/ref-36","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_29_2023\/ref-37","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_29_2023\/ref-38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-39","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (Equator): Results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_29_2023\/ref-40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/0005-2795(75)90349-9","article-title":"POS0198 efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: Results from a phase 2, randomized, double-blind, placebo-controlled","volume":"80;Suppl 1","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-41","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-42","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-43","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_29_2023\/ref-44","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: An observational cohort study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_29_2023\/ref-45","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_29_2023\/ref-47","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: First approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.25259\/IJDVL_29_2023\/ref-48","doi-asserted-by":"publisher","DOI":"10.1002\/art.42355","article-title":"Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO Program [abstract]","volume":"74(Suppl 9)","author":"Warren","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_29_2023\/ref-49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jaut.2016.10.009","article-title":"Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"J Autoimmun"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/janus-kinase-inhibitors-for-the-treatment-of-psoriatic-arthritis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/janus-kinase-inhibitors-for-the-treatment-of-psoriatic-arthritis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T06:30:22Z","timestamp":1708497022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/janus-kinase-inhibitors-for-the-treatment-of-psoriatic-arthritis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":48,"alternative-id":["10.25259\/IJDVL_29_2023"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_29_2023","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"article-number":"186"}}